Phase 2 Start
PLYX: Phase 2 Start: An Open-Label, Multicenter, Phase 2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pr
December 1, 2026 · lysosomal. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- Polaryx Therapeutics Inc. (PLYX)
- Drug
- lysosomal
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: An Open-Label, Multicenter, Phase 2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pr
- Drug
- lysosomal
- Indication
- CLN2; Krabbe Disease; Lysosomal Storage Disorders